• +228 872 4444
  • +775 872 4444
  • contact@email.com
QNET | EU, UK & CH Representative & Regulatory Partner
  • Home
  • About QNET
  • News/Insights
  • Contact
  • Services
Sign In

The EU Packaging and Packaging Waste Regulation (PPWR)

News-Insights

(August 12, 2026)

Regulation (EU) 2025/40 on Packaging and Packaging Waste, known as the PPWR, introduces a harmonized European framework for packaging and packaging waste.

The PPWR entered into force on 11 February 2025 and has generally applied since 12 August 2026. Some requirements are introduced through later implementation dates and delegated or implementing legislation.

The Regulation applies alongside the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Medical Devices Regulation (IVDR). Compliance with the MDR or IVDR does not automatically demonstrate compliance with the PPWR.

Which packaging is covered?

The PPWR applies broadly to packaging placed on the EU market, regardless of the packaging material, the type of product it contains, or where the packaging was manufactured.

For medical devices and IVDs, this may include:

  • immediate or primary product packaging;
  • sterile-barrier systems and protective packaging;
  • secondary or grouped packaging;
  • cartons, trays, pouches, bottles, tubes and protective inserts;
  • transport and distribution packaging;
  • pallets, pallet wrapping and straps; and
  • e-commerce packaging.

Identify and assess each level and component of the packaging system. A packaging component is not automatically outside the scope merely because it is used for a regulated medical device.

What does the PPWR require?

Depending on the packaging type and the applicable implementation date, manufacturers and other economic operators may need to address requirements concerning:

  • substances present in packaging;
  • minimization of packaging weight and volume;
  • recyclability and design for recycling;
  • minimum recycled content in plastic packaging;
  • compostable or reusable packaging;
  • packaging labelling and material identification;
  • reuse and packaging-waste prevention targets;
  • technical documentation;
  • an EU Declaration of Conformity; and
  • Extended Producer Responsibility (EPR) registration and reporting.

Not all requirements apply from the same date. A product-specific and packaging-specific assessment is therefore necessary.

Are medical device packages exempt?

Medical device packaging is not generally exempt from the PPWR.

The Regulation provides specific derogations or adjusted timelines for certain contact-sensitive packaging used for medical devices and IVDs. These provisions recognize that changes to packaging material may affect:

  • patient and user safety;
  • biological compatibility;
  • contamination control;
  • sterile-barrier integrity;
  • shelf life;
  • device functionality and performance; or
  • compatibility between the device and its packaging.

These provisions are limited to particular PPWR requirements and packaging categories. They should not be interpreted as a complete exemption from the Regulation.

The applicability of a derogation must be assessed and documented for each relevant packaging component.

Standard or stock packaging components

Many medical device manufacturers purchase standard packaging components from specialist packaging suppliers. Examples include stock cartons, pouches, trays, bottles, tubes and transport boxes.

The packaging supplier should provide appropriate supporting information, such as:

  • material and composition specifications;
  • substance declarations;
  • recycled-content information, where applicable;
  • test reports and compliance statements;
  • information necessary to demonstrate recyclability;
  • identification of relevant packaging standards; and
  • its PPWR EU Declaration of Conformity, where required.

Purchasing a standard packaging component does not by itself demonstrate that the final packaged medical device complies with all applicable requirements.

The medical device manufacturer should determine whether the information received is adequate and whether the selected packaging is suitable for its intended application. It must also assess the complete packaging configuration, including the combination of primary, secondary, and transport packaging.

Packaging performed by a contract manufacturer

Medical device manufacturers frequently outsource production and packaging activities to a contract manufacturer. The contract manufacturer does not automatically become the responsible PPWR manufacturer merely because it:

  • purchases the packaging materials;
  • packages the medical device;
  • performs packaging validation; or
  • arranges transport and distribution.

Responsibility depends on the actual arrangement, including:

  • who designs or specifies the packaging;
  • who has the packaging or packaged product manufactured;
  • under whose name or trademark it is placed on the market;
  • whether the packaging is standard or customer-specific;
  • who imports the packaging or packaged product into the EU; and
  • whether an existing packaging format is subsequently modified.

The legal manufacturer of the medical device may therefore also qualify as a manufacturer under the PPWR where it has the packaging or packaged product manufactured and places it on the market under its own name or trademark.

The roles and responsibilities should be determined for each supply chain. They should be documented in (1) the quality agreement, (2) manufacturing agreement, or (3) a separate packaging responsibility matrix.

The agreement should address at least:

  • responsibility for PPWR classification and assessment;
  • supplier-data collection;
  • packaging testing and validation;
  • preparation of technical documentation;
  • preparation and signing of the PPWR Declaration of Conformity;
  • packaging marking and labelling;
  • change notification and change control;
  • document-retention periods; and
  • cooperation with competent and market-surveillance authorities.

Outsourcing packaging operations does not automatically transfer the legal manufacturer's regulatory responsibility.

Medical device packaging verification and validation

In addition to PPWR compliance, the legal manufacturer remains responsible under the MDR or IVDR for demonstrating that the packaging protects the medical device throughout its claimed shelf life and under the intended storage, handling and transport conditions.

Depending on the device and packaging system, documented evidence may be required for:

  • packaging integrity;
  • sterile-barrier integrity;
  • seal strength and seal-process validation;
  • accelerated and real-time aging;
  • storage conditions;
  • distribution and transport simulation;
  • protection against mechanical damage;
  • contamination control;
  • biological or chemical compatibility;
  • packaging-device interaction; and
  • legibility and durability of labels.

Relevant verification and validation evidence should be included in, or clearly referenced from, the medical device technical documentation.

Transport packaging should therefore not only be assessed as packaging under the PPWR. It should also be demonstrated that it adequately protects the medical device during foreseeable transportation, storage and handling.

Involvement of the notified body

For devices subject to notified body involvement, packaging documentation may be reviewed as part of the MDR or IVDR conformity assessment or during quality-management-system audits.

The notified body may, for example, review:

  • sterile-packaging validation;
  • transport and distribution studies;
  • shelf-life evidence;
  • supplier controls;
  • outsourced packaging processes;
  • change-control procedures; and
  • the relationship between packaging specifications and the device risk-management file.

This review concerns the conformity of the medical device under the MDR or IVDR. It should not automatically be regarded as an independent assessment or certification of PPWR compliance.

The manufacturer remains responsible for establishing and maintaining the applicable PPWR technical documentation and Declaration of Conformity.

EU Declaration of Conformity and technical documentation

Where required, PPWR compliance must be supported by packaging technical documentation and an EU Declaration of Conformity.

The documentation should be sufficiently detailed to identify:

  • the packaging and its intended use;
  • the packaging components and materials;
  • the applicable PPWR requirements;
  • applicable derogations and their justification;
  • specifications, calculations and test evidence;
  • the standards or technical methods used;
  • supplier declarations and supporting records;
  • the responsible manufacturer; and
  • the person authorized to sign the Declaration of Conformity.

The PPWR Declaration of Conformity is legally distinct from the MDR or IVDR Declaration of Conformity for the medical device. Although documentation may be coordinated within the manufacturer’s quality system, the different legal bases and responsible parties must remain clearly identifiable.

Role of the EU Authorized Representative

Appointment as an EU Authorized Representative under the MDR or IVDR does not automatically include representation under the PPWR.

A medical device manufacturer established outside the EU should therefore determine separately:

  • whether it qualifies as a manufacturer or another economic operator under the PPWR;
  • whether a PPWR Authorized Representative is required or appropriate;
  • which PPWR activities are included in the written mandate; and
  • which party is responsible for Extended Producer Responsibility obligations in each Member State.

Any PPWR responsibilities assigned to a representative should be expressly included in a written mandate. They should not be assumed to form part of an existing MDR or IVDR Authorized Representative agreement.

Recommended actions for manufacturers

Medical device and IVD manufacturers should:

  1. Prepare an inventory of all packaging levels and components.
  2. Identify the packaging supplier, contract manufacturer, importer, and other relevant parties for each packaging configuration.
  3. Determine the responsible PPWR economic operator.
  4. Identify the requirements and implementation dates applicable to each packaging component.
  5. Obtain material specifications, declarations and supporting evidence from suppliers.
  6. Determine whether any medical-device-specific derogation applies and document the justification.
  7. Confirm that packaging and transport verification or validation remains adequate.
  8. Review contracts and quality agreements with packaging suppliers and contract manufacturers.
  9. Prepare or update the required PPWR technical documentation and EU Declaration of Conformity.
  10. Establish procedures for supplier changes, packaging changes, document retention and regulatory monitoring.

How QNET can assist

QNET can support medical device and IVD manufacturers with:

  • PPWR scope and applicability assessments;
  • packaging inventories and responsibility matrices;
  • identification of responsible economic operators;
  • review of supplier and contract-manufacturer arrangements;
  • assessment of medical-device-specific derogations;
  • review of packaging technical documentation;
  • PPWR Declaration of Conformity templates;
  • integration of PPWR controls into the quality-management system; and
  • coordination of PPWR requirements with MDR and IVDR packaging documentation.

Early assessment is particularly important where packaging activities have been outsourced or where supporting information must be obtained from multiple packaging suppliers.

This publication provides general regulatory information and does not constitute legal advice. Assess PPWR responsibilities and applicable derogations for the specific packaging, product, and supply-chain configuration.

Official references:

  • -   Regulation (EU) 2025/40, Packaging and Packaging Waste Regulation
  • -        European Commission – Packaging Waste Policy
  • -        European Commission Notice – PPWR guidance for Northern Ireland
  • -        Guidance document on Packaging and Packaging Waste Regulation (PPWR)
  • -        FAQ on Packaging and Packaging Waste Regulation (PPWR)

 

EU MDR/IVDR Developments: What Manufacturers Should Prepare for in 2026

News-Insights 30 December 2025

The European regulatory landscape for medical devices and IVDs continues to evolve. In December 2025, the European Commission published a proposal to simplify selected elements of the MDR and IVDR, while preserving patient safety and regulatory oversight. At the same time, EUDAMED is moving from preparation to mandatory use, with clear deadlines set for 2026.

  • For manufacturers supplying the EU market, this creates a familiar challenge: regulatory change is unavoidable, but disruption is not. Organisations that prepare early can maintain market continuity, avoid last-minute remediation, and reduce compliance risk.

 

What is changing (at a glance)

MDR/IVDR: targeted simplification under discussion

The Commission’s proposal signals a clear intention to reduce unnecessary administrative burden and address known bottlenecks in the regulatory system. While the proposal is not yet law, it reflects strong regulatory momentum to stabilise the European market and prevent further loss of medical devices and IVDs.

  • For manufacturers, the key message is reassurance: regulators recognise the pressure on the system and are acting to improve it.

 

EU Authorised Representative (EAR) role: more flexibility, clearer collaboration

The proposal also touches on the role of the European Authorised Representative (EAR). The direction of travel is toward greater contractual flexibility, allowing manufacturers and EARs to agree on additional support activities where appropriate. This is positive news for non-EU manufacturers, as it enables a more integrated compliance model. At the same time, it reinforces the importance of working with an EAR that operates under a robust quality system, with clearly defined roles and responsibilities.

  • Business benefit: a well-structured EAR partnership can move beyond “formal representation” and become a practical extension of the manufacturer’s regulatory organisation.

 

EUDAMED: mandatory use from May 2026

EUDAMED is no longer a future concept, it is becoming a regulatory reality.

Following the European Commission’s functionality notice published on 27 November 2025, mandatory use of the first four EUDAMED modules will apply from 28 May 2026:

  • Actor Registration
  • UDI and Device Registration
  • Notified Bodies and Certificates
  • Market Surveillance

This milestone applies regardless of any future MDR/IVDR amendments. This means in practice:

  • Compliance will depend not only on registering data, but on maintaining accurate, controlled, and auditable information over time. Organisations that treat EUDAMED as a one-off registration exercise risk operational gaps and regulatory exposure.

 

Increased focus on Post-Market Surveillance (PMS) and lifecycle control

Recent guidance and policy discussions confirm a continued shift toward stronger post-market surveillance (PMS), vigilance, and lifecycle oversight. Rather than adding unnecessary complexity, the intent is to ensure that real-world performance and safety data are systematically collected and acted upon.

  • For manufacturers, this trend reinforces the value of:
    • scalable PMS processes,
    • structured complaint and vigilance workflows, and
    • clear interfaces between regulatory, quality, and operational teams.

 

How manufacturers can prepare – without over-investing

Based on current developments, several “no-regret” actions make sound business sense:

Establish EUDAMED readiness early

  • Define ownership of EUDAMED data, align internal stakeholders, and ensure device and certificate information is maintained consistently over time.

Strengthen your EAR collaboration model

  • Review your AR agreement to ensure clarity of scope, accountability, and escalation pathways. A strong AR relationship reduces friction with authorities and supports continuity during audits, inspections, and market surveillance activities.

Align PMS with operational reality

  • Ensure that PMS and vigilance are integrated into daily operations, not treated as theoretical or purely regulatory exercises.

 

How QNET supports manufacturers

  • QNET works with international medical device and IVD manufacturers as a long-term regulatory partner, providing:
    • EU Authorised Representative (EAR) services under a compliant ISO 13485 quality management system
    • Practical EUDAMED readiness and data governance support
    • PMS and vigilance framework design and implementation
    • Strategic regulatory guidance across the EU, UK, and Switzerland

Our approach is pragmatic, risk-based, and designed to support business continuity, not just regulatory compliance.

 

Looking ahead

  • While the MDR/IVDR proposal continues through the legislative process, EUDAMED deadlines are already fixed. Manufacturers that act early will be better positioned to adapt smoothly, avoid compliance surprises, and maintain uninterrupted access to the European market.
  • Regulatory change does not have to slow your business if it is managed proactively.

 

Call to action

  • Would you like to assess your EUDAMED and MDR/IVDR readiness for 2026?
    QNET can support you with a focused, practical review tailored to your product portfolio and market strategy.

QMSR Transition Readiness Checklist

News-Insights

A. Quality Management System Alignment

✔ Confirm transition from QSR (1996) to QMSR (2026) across all internal documentation.
✔ Update your Quality Manual to reflect ISO 13485:2016 requirements.
✔ Verify the use of ISO 9000:2015 Clause 3 for terminology.
✔ Perform a QMS gap analysis comparing your current system to ISO 13485.
✔ Ensure all risk-based processes (design, manufacturing, supplier control, PMS) align with ISO 13485 and FDA expectations.

 

B. Documentation & Process Updates

✔ Map all QMS elements directly to ISO 13485 clauses (as recommended in FDA draft guidance).
✔ Update procedures for:

  • Document control
  • Design controls
  • Risk management
  • CAPA
  • Complaint handling
  • Supplier management
    ✔ Ensure your Device Master Records (DMR) and Design History Files (DHF) reflect ISO structure.

 

C. FDA Submission Requirements (PMA/HDE)

✔ Confirm DUNS numbers for all manufacturing, packaging, and sterilization sites.
✔ Prepare or update your UDI assignment & maintenance plan.
✔ Check labeling and regulatory submissions for consistency with ISO 13485 processes.
✔ Prepare a cross-table showing where FDA-required elements are addressed in ISO-aligned procedures.

 

D. Internal and Supplier Audits

✔ Schedule an ISO 13485–aligned internal audit before February 2026.
✔ Verify suppliers’ compliance with ISO 13485 or equivalent requirements.
✔ Document evidence of supplier risk assessments and ongoing monitoring.

 

E. Training & Change Management

✔ Train management and staff on the new QMSR terminology and expectations.
✔ Update competency matrices and training records.
✔ Communicate the QMSR effective date: 2 February 2026.

 

F. Post-Market Activities

✔ Align complaint handling, vigilance, and PMS with:

  • ISO 13485
  • FDA reporting requirements
    ✔ Ensure traceability aligns with UDI and ISO 13485 Clause 7.5.9.2.
    ✔ Confirm that PMS data feeds into management review and CAPA.

 

G. Management Review

✔ Add QMSR transition as a standing agenda item.
✔ Review:

  • Gap analysis outcomes
  • Audit results
  • UDI readiness
  • Supplier compliance
  • PMS and CAPA trends
    ✔ Approve update actions and allocate resources.

 

H. Final Readiness Before 2 February 2026

✔ Validate that all updated procedures are approved, implemented, and communicated.
✔ Replace QSR terminology in documents with QMSR/ISO-based terms.
✔ Ensure that all submission-relevant information (UDI plan, DUNS numbers, mapping tables) is ready for FDA inspections.
✔ Maintain validation records for software, equipment, and critical processes according to ISO 13485.

 

 

 

 

US FDA Finalizes QMSR: Transition to ISO 13485 Harmonization Accelerates

News-Insights

 

The US Food and Drug Administration (FDA) is entering the final phase of one of the most significant regulatory transitions for medical devices in decades. After years of discussion, public consultation, and alignment efforts, the FDA has confirmed that its long-standing Quality System Regulation (QSR) will be replaced by the Quality Management System Regulation (QMSR). This shift formally harmonizes US quality requirements with ISO 13485:2016, the global cornerstone standard for medical device quality management.

For many manufacturers—particularly those active in global markets—this transition is not a surprise. The industry has been anticipating this move for several years, and many organizations have already begun aligning their quality systems with ISO 13485. At QNET, we support numerous clients worldwide in adopting or strengthening ISO 13485-based quality systems, including United Sports Brands (USB), whose QMS is already structured in accordance with ISO 13485:2016.

With QMSR, international alignment will increase, regulatory overlap will decrease, and manufacturers will benefit from a more consistent and predictable global compliance pathway.

 

Background: From QSR to QMSR

1. QSR Origins (1996)

Since 1996, US medical device manufacturers have been required to comply with 21 CFR Part 820, commonly known as the Quality System Regulation.

The regulation established Good Manufacturing Practice (GMP) requirements to ensure safety and effectiveness during design, production, packaging, labeling, storage, and servicing.

 

2. FDA Publishes the Final Rule (2024)

On 2 February 2024, the FDA published the final rule titled “Medical Devices; Quality System Regulation Amendments” in the Federal Register.

The rule implements two major changes:

  • Renaming QSR → QMSR (Quality Management System Regulation)
  • Harmonization with international QMS requirements, specifically ISO 13485:2016

Through incorporation by reference, the FDA formally adopts:

  • ISO 13485:2016 – Quality management systems for medical devices
  • ISO 9000:2015, Clause 3 – Terms and definitions

 

3. FDA Draft Guidance on Submissions (2025)

On 27 October 2025, the FDA released draft guidance describing the QMS-related information expected in new submissions, including:

  • DUNS numbers for all manufacturing sites
  • A UDI assignment and maintenance plan
  • A clear mapping of QMS processes to ISO 13485 clauses
  • Clarified expectations for PMA and HDE submissions under QMSR

This draft marks a shift away from the US-centric legacy QSR approach toward a globally harmonized, risk-based framework.

 

4. Effective Date

The QMSR becomes fully effective on 2 February 2026, replacing the existing QSR through amendments to 21 CFR Part 820. From that date onward, ISO 13485 compliance is no longer only “helpful”—it becomes the foundational requirement for all US medical device manufacturers.

 

What This Means for Manufacturers

Global Alignment and Reduced Regulatory Burden

With ISO 13485 at the core of US quality requirements, manufacturers operating in Europe, the UK, Switzerland, and other ISO-aligned markets will benefit from streamlined compliance and less duplication.

 

More Predictable Inspections

FDA investigators will evaluate quality systems using ISO-aligned terminology and structure. Organizations already operating under ISO 13485 will recognize most requirements, though the FDA retains certain US-specific expectations, including complaint handling, CAPA, and reporting obligations.

 

Updated Submission Requirements

Risk management, UDI strategy, and organizational traceability (including DUNS number accuracy) will now be integral parts of PMA and HDE submissions.

 

Stronger Emphasis on Risk-Based Processes

Like ISO 13485, QMSR reinforces a lifecycle approach, integrating risk management into design, manufacturing, and post-market activities.

 

How QNET Supports Clients During the QMSR Transition

QNET is already working with manufacturers preparing for the February 2026 enforcement date. Our support includes:

  • Gap assessments between existing QSR-based systems and ISO 13485:2016
  • Implementation or upgrading of ISO 13485-aligned QMS structures
  • Documentation mapping for FDA submissions under the draft guidance
  • PMS, vigilance, and UDI strategy development
  • Internal audits conforming to ISO 13485, FDA expectations, and global AR/UKRP/CH-REP requirements

Because QNET operates across the EU, UK, Switzerland, and the US, clients benefit from unified guidance that addresses both US and international regulatory expectations.

 

Conclusion

The FDA’s shift from QSR to QMSR marks a historic milestone in international regulatory alignment. With ISO 13485 at the center of the new rule, manufacturers will face a more consistent global framework—one that supports quality, innovation, and patient safety. Organizations that have already adopted ISO 13485 are well-positioned for the transition, while others will need to begin preparing now to meet the February 2026 deadline.

 

QNET will continue to follow developments closely and provide further updates and practical guidance to our clients in the coming months.

ISO 13485 Confirmed in 2025 — No Annex SL Update

News-Insights 02 November 2025

 ISO has completed the 2025 systematic review of ISO 13485:2016 and confirmed the current edition. In practice, that means there is no new version and no adoption of the Annex SL / High-Level Structure at this time.

Why this matters

  • Manufacturers and suppliers can continue using existing ISO 13485:2016-based QMS without re-structuring to Annex SL.
  • Alignment efforts with regulators (e.g., FDA QMSR’s incorporation of ISO 13485) remain unaffected.
  • If ISO decides to revise ISO 13485 in future cycles, Annex SL could resurface; for now, the 2016 edition remains current.

 

What manufacturers should do now

  1. Continue operating under ISO 13485:2016 — no changes to your QMS structure or documentation are required.
  2. Monitor regulatory alignment — the FDA’s Quality Management System Regulation (QMSR) and MDR/IVDR expectations remain based on the 2016 version.
  3. Verify certificate validity — certification bodies will maintain current ISO 13485:2016 certificates; ensure your audit cycle remains on track.
  4. Stay informed — watch for official announcements from ISO/TC 210 and your national standards body regarding any future revision plans.
  5. Communicate with your supply chain — confirm suppliers and subcontractors are aware that no revision or Annex SL restructuring applies.

Sources: ISO catalogue (status “confirmed in 2025”); ISO/TC 210 background on possible HLS adoption if revised; national member communications on the 2025 review; industry updates from TC 210 participants.

Disclaimer
This article is intended for informational purposes only and reflects QNET’s interpretation of publicly available information from ISO and national standards bodies as of November 2025. ISO 13485 remains under the ownership and control of the International Organization for Standardization (ISO). Users should always consult the official ISO catalogue and their certification body for authoritative updates or requirements.

  1. Global Regulatory Shifts: What Companies Need to Know about Market Access and Representation
  2. ISO 10993-1:2025 – A New Chapter in Biological Safety for Medical Devices
  3. Insight: Navigating the EU In Vitro Diagnostic Regulation (IVDR)
  4. The New EU Product Liability Directive (2024/2853): Implications for Medical Device Manufacturers

Page 1 of 2

  • 1
  • 2

Cookie Policy

  • Cookie Policy
  • Terms of Use
  • Privacy Policy
  • Home
  • About QNET
  • News/Insights
  • Contact
  • Services